Our findings of in vivo anti-inflammatory effects of olaparib, a PARP inhibitor approved for human cancer therapy, may justify initiation of clinical trials for repurposing this drug for IBD therapy. This evidence concerns the gene PARP1 and inflammatory bowel disease.